Recent News

• 09.10.2025 - Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis
• 09.02.2025 - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 08.11.2025 - Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress
• 08.05.2025 - Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025
• 08.01.2025 - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 07.01.2025 - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 06.03.2025 - Karyopharm to Present at the Jefferies Global Healthcare Conference
• 06.02.2025 - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.11.2025 - EX-99.1 EX-99.1
• 08.11.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.11.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 08.11.2025 - 8-K Current report
• 07.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.16.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.11.2025 - EX-99.1 EX-99.1